EQS-News: Marinomed Biotech AG / Key word(s): Alliance
Marinomed Biotech AG announces partnership for Budesolv in Switzerland
06.06.2025 / 15:20 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG announces partnership for Budesolv in Switzerland
• Marinomed has signed a binding term sheet with a Swiss pharma partner
for the development and marketing of Budesolv for the Swiss market
• With this Marinomed is eligible to receive milestone payments and
royalties
• Switzerland to serve as a reference country for certain markets abroad
Korneuburg, Austria, June 6^th , 2025 - Marinomed Biotech AG (VSE:MARI)
announces that it has signed a binding term sheet with a Swiss
pharmaceutical company for the development and marketing of Budesolv for
the Swiss market. The new partner has been granted exclusive rights to
sell and distribute Budesolv under its own brand. The deal includes the
final development steps that are necessary for filing the marketing
authorization in Switzerland. Marinomed is eligible to receive undisclosed
upfront and milestone payments as well as royalties on sales. Marinomed
retains all rights outside the territory and has the right to use the
dossier compiled for Switzerland outside the territory.
“This is an important step for Marinomed and Budesolv. Following the
encouraging communication with Swissmedic we are excited to develop this
project to the next level. We have found the perfect partner for
registration and the first launch of Budesolv”. Andreas Grassauer, CEO of
Marinomed, mentions. “We are confident that this deal is the first trigger
for several other partnerships to come. We are convinced that a
registration in Switzerland will enable opportunities in a series of other
markets abroad.”
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: (1)pr@marinomed.com
E-Mail: (2)ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise.
══════════════════════════════════════════════════════════════════════════
06.06.2025 CET/CEST This Corporate News was distributed by EQS Group.
www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2151616
End of News EQS News Service
2151616 06.06.2025 CET/CEST
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2151616&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf
References
Visible links
1. mailto:pr@marinomed.com
2. mailto:ir@marinomed.com
OTS original text press release with the exclusive in terms of content of the sender – www.ots.at |